Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease

Atherosclerosis

Volumn 234, Issue 2, 2014, Pages 441-445

  Li, Sha ^a   Guo, Yuan Lin ^a   Xu, Rui Xia ^a   Zhang, Yan ^a   Zhu, Cheng Gang ^a   Sun, Jing ^a   Qing, Ping ^a   Wu, Na Qiong ^a   Jiang, Li Xin ^a   Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Coronary artery disease; Proprotein convertase subtilisin kexin type 9; White blood cell count

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PCSK9 PROTEIN, HUMAN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; AGED; BLOOD; CHI SQUARE DISTRIBUTION; CHINA; ENZYMOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; RISK FACTOR; STATISTICAL MODEL;

AGED; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHINA; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEUKOCYTE COUNT; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPROTEIN CONVERTASES; RISK FACTORS; SERINE ENDOPEPTIDASES;

EID: 84900854191     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.04.001     Document Type: Article

References (26)

1. Li J.-J., Li Y.-S., Fang C.-H., et al. Effects of simvastatin within two weeks on anti-inflammatory cytokine interleukin 10 in patients with unstable angina. Heart 2006, 92:529-530.
2. Lambert G., Sjouke B., Choque B., Kastelein J.J., Hovingh G.K. The PCSK9 decade. JLipid Res 2012, 53:2515-2524.
3. Liu J., Guo Y.-L., Xu R.-X., Li J.-J. Rapid effects of different lipid-lowering drugs on PCSK9 in humans. Clin Lipidol 2013, 8:519-524.
4. Guo Y.-L., Liu J., Xu R.-X., et al. Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9. Clin Drug Invest 2013, 33:877-883.
5. Stock J. Improving the care of high-risk patients: the potential of PCSK9. Atherosclerosis 2014, 232:420-422.
6. Denis M., Marcinkiewicz J., Zaid A., et al. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation 2012, 125:894-901.
7. Urban D., Pöss J., Böhm M., Laufs U. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. JAm Coll Cardiol 2013, 62:1401-1408.
8. Mbikay M., Mayne J., Chrétien M. Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions. JDiabetes 2013, 5:391-405.
9. Feingold K.R., Moser A.H., Shigenaga J.K., et al. Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun 2008, 374:341-344.
10. Tang Z., Jiang L., Peng J., et al. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kB activation in THP-1-derived macrophages. Int J Mol Med 2012, 30:931-938.
11. Poirier S., Mayer G., Benjannet S., et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. JBiol Chem 2008, 283:2363-2372.
12. Ranheim T., Mattingsdal M., Lindvall J.M., et al. Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9. JCell Physiol 2008, 217:459-467.
13. Ortega E., Gilabert R., Nuñez I., et al. White blood cell count is associated with carotid and femoral atherosclerosis. Atherosclerosis 2012, 221:275-281.
14. Hasegawa T., Negishi T., Deguchi M. WBC count, atherosclerosis and coronary risk factors. JAtheroscler Thromb 2002, 9:219-223.
15. Madjid M., Fatemi O. Components of the complete blood count as risk predictors for coronary heart disease. Tex Heart Inst J 2013, 40:17-29.
16. Taylor J. New ESC guidelines published on stable coronary artery disease. Eur Heart J 2013, 34:2927-2928.
17. Cariou B., May C.L., Costet P. Clinical aspects of PCSK9. Atherosclerosis 2011, 216:258-265.
18. Sabatine M.S., Morrow D.A., Cannon C.P., et al. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction 18 trial) substudy. JAm Coll Cardiol 2002, 40:1761-1768.
19. Lee C.D., Folsom A.R., Nieto F.J., et al. White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and White men and women: atherosclerosis risk in communities study. Am J Epidemiol 2001, 154:758-764.
20. Madjid M., Awan I., Willerson J.T., Casscells S.W. Leukocyte count and coronary heart disease: implications for risk assessment. JAm Coll Cardiol 2004, 44:1945-1956.
21. Welder G., Zineh I., Pacanowski M.A., et al. High-dose atorvastatin cause a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. JLipid Res 2010, 51:2714-2721.
22. Leigh S.E., Leren T.P., Humphries S.E. Commentary PCSK9 variants: a new database. Atherosclerosis 2009, 203:32-33.
23. Dey S., Flather M.D., Devlin G., et al. Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart 2009, 95:20-26.
24. Frink R.J. Gender gap, inflammation and acute coronary disease: are women resistant to atheroma growth? Observations at autopsy. JInvasive Cardiol 2009, 21:270-277.
25. Constantinides A., Kappelle P.J., Lambert G., Dullaart R.P. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9. Arch Med Res 2012, 43:11-14.
26. Evans D., Beil F.U. The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women. BMC Med Genet 2006, 7:66.